All rights reserved. No reuse allowed without permission.

Wearable Data Reveals distinct Characteristics of Individuals with
Persistent Symptoms after a SARS-CoV-2 Infection
Katharina Ledebur ^{1,2,3[†]*} , Marc Wiedermann ^{3[†]} , Christian Puta ^{4,5,6} , Stefan Thurner ^{1,2,7} ,
Peter Klimek ^{1,2,8,9} , Dirk Brockmann ^{3,10,11}
Institute of the Science of Complex Systems, CoDAS, Medical University of Vienna
Spitalgasso 23 A 1000 Vienna, Austria
$\frac{2}{2} = \frac{1}{2} + \frac{1}{2} = \frac{1}{2} + \frac{1}{2} = \frac{1}{2} + \frac{1}{2} + \frac{1}{2} + \frac{1}{2} + \frac{1}{2} = \frac{1}{2} + \frac{1}$
Complexity Science Hub, Josefstadter Strasse 39, A-1080 Vienna, Austria
³ Computational Epidemiology Group, Robert Koch Institute, 13353 Berlin, Germany
⁴ Department of Sports Medicine and Health Promotion, Friedrich-Schiller-University Jena,
Jena, Germany
⁵ Center for Sepsis Control and Care (CSCC), Jena University
Hospital/Friedrich-Schiller-University Jena, Jena, Germany
⁶ Center for Interdisciplinary Prevention of Diseases Related to Professional Activities, Jena,
Germany
⁷ Santa Fe Institute, 1399 Hyde Park Road, Santa Fe, NM 87501, USA
⁸ Supply Chain Intelligence Institute Austria, Josefstädter Strasse 39, A-1080 Vienna, Austria
⁹ Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet,
SE-17177 Stockholm, Sweden
¹⁰ Center Synergy of Systems & Center for Interdisciplinary Digital Sciences, TUD Dresden
University of Technology, 01069 Dresden, Germany
¹¹ Faculty of Biology, TUD Dresden University of Technology, 01069 Dresden, Germany
* ledebur@csh.ac.at

23

Abstract

Evidence on long-term health effects of SARS-CoV-2 infection remains scarce. Using a wearable-24 derived behavioral and physiological dataset (n = 20,815), we identified 137 individuals character-25 ized by self-reported persistent fatigue and shortness of breath following a SARS-CoV-2 infection. 26 Compared with symptom-free COVID-19 positive and negative controls, these individuals had 27 higher resting heart rates (mean difference 2.37/1.49 bpm) and lower daily step counts (mean 28 3.030/2.909 steps fewer), even at least three weeks prior to SARS-CoV-2 infection. In addition, 29 persistent COVID-19 symptoms were associated with a significant reduction in mean quality of life 30 (WHO-5, EQ-5D), even before infection. Analysis of individual wearable time series suggests that 31 individuals with persistent symptoms may have been more exposed to pre-existing health condi-32 tions/lower fitness levels prior to SARS-CoV-2 infection. Our study demonstrates the potential of 33 wearable devices to track physiological and physical activity dynamics under natural conditions in 34 the context of infectious and chronic diseases. 35

36 Introduction

37 SARS-CoV-2 infections exhibit a diverse range of long-term impacts on individual health. The WHO

defines post-COVID-19 condition (PCC) as the continuation or development of new symptoms 3 months

 $_{39}$ afte Not the initial physical restances the theorem is the state of the theorem in the state of the theorem is the state of the theorem is theorem is the theorem is the theorem is the theore

40 explanation 1. PCC is a multi-systemic condition 2 that has led to increased demand for health care

41 due to increased disease burden 3. Studies on persistent symptoms post-SARS-CoV-2 infection vary

All rights reserved. No reuse allowed without permission.

widely in design, including differences in symptoms studied, follow-up duration, and study populations
[4] [7]. In addition, challenges in data availability - such as a lack of adequate control cohorts, insufficient pre-infection health data, a focus on severe cases, and a reliance on subjective self-reports or
infrequent measurements - have limited our understanding of persistent symptoms post-SARS-CoV-2
and those affected by it [5], [8]-[12].

47

⁴⁸ Data from wearable devices such as smartwatches or fitness trackers, offer a novel approach to un-⁴⁹ derstanding the long-term impact of SARS-CoV-2 by providing objective measurements of heart rate, ⁵⁰ physical activity, step count, and sleep duration 13–15. Combining this data with individual symp-⁵¹ tom reports not only enables the detection of critical events (e.g infection onset) but also also provides ⁵² a deeper understanding of how consequences of a SARS-CoV-2 infection affect individual physiology ⁵³ and behavior 16–18. These datasets provide a unique opportunity to establish pre-infection health ⁵⁴ baselines through continuous, non-invasive, and cost-effective measurements.

55

During the COVID-19 pandemic, several initiatives were launched to collect such data [18-20]. One 56 such initiative is the Corona Data Donation project 13, 21–23 by the Robert Koch Institute, Ger-57 many's federal agency for public health research. Between April 2020 and December 2022, over 500,000 58 voluntary participants registered for the project, obtained and activated the Corona Data Donation 59 Application (CDA), and over 120,000 submitted more than 600 days of their basic wearable data (such 60 as resting heart rate (RHR) and step count) using a custom-made smartphone application. In addition 61 to daily averages, wearable data is available with exceptional resolution, down to the order of seconds. 62 This permits a deep analysis of wearable-derived time-series, e.g. short high-intensity activities, regu-63 larities, and potential disruptions under natural conditions. Moreover, the high temporal resolution of 64 the data and its coverage of long periods of time permit a detailed analysis of wearable data signals in 65 all phases of a SARS-CoV-2 infection, i.e. the acute phase (from the week of the positive SARS-CoV-2 66 test to four weeks after the test), the sub-acute phase (four weeks to 12 weeks after the test), and the 67 post-acute phase (12 weeks after the test date) [24]. One can clearly distinguish between individuals 68 exhibiting weak regulation responses following infection (Fig. 1a,b) from those with strong ones (Fig. 69 **1**c.d). Participants also completed monthly and weekly surveys about COVID-19 tests, symptoms as 70 well as their subjective wellbeing and health-related Quality of Life (QoL). 71

72

We leveraged the unique combination of wearable data and survey data from the Corona Data Donation project to analyze the physical health of individuals reporting persistent symptoms following a SARS-CoV-2 infection. We focused on cohort-level averages of physiological metrics (specifically RHR) behavioral (step count) metrics. To make sense of the observed changes in wearable data, we then compared these objective measures with self-reported QoL (WHO-5 and EQ-5D) to show how signals in passively measured health data translate directly into subjectively experienced changes or limitations in daily life.

Our study aims to investigate resting heart rate, step count, subjective symptoms report and self reported quality of life to analyse possible interactions with pre-existing health conditions before infection, time-course of infection and post-infection phases. To this end, we first identified a cohort of individuals that reported a positive SARS-CoV-2 test (COVID - 19[+]) along with their negative controls (COVID - 19[-]). Within COVID - 19[+] we compared those that reported long-lasting symptoms (COVID - 19[+]PS) with those that did not (COVID - 19[+]NS) to characterize the PCC phenotype.

87 Results

⁸⁸ Increased frequency of reports on prolonged symptoms after infection

We evaluated the relative frequency of the reported symptoms of shortness of breath and fatigue in the *full cohort* (Fig.2) in pre- (< 0 weeks to the reported COVID-19 test), acute- (0-4 weeks), subacute (5-12 weeks), and post-phase (>12 weeks) 24. During the acute phase of infection, fatigue was reported as a symptom by up to 69.76% (SE = 0.54%) of individuals in COVID - 19[+] and



3 -2 -1 0 1 2 3 Day since Test [d] Fig 1. Time series of two representative individuals from the CDA population (a-d) and cohort diagram (e-h). Average daily heart rate [bpm] (a,c) and step counts (b,d) per 15 minutes relative to the day of the reported positive SARS-CoV-2 test (shaded grey area). Heart rate and step count for an individual without persistent symptoms 10 days before and after a reported positive test (a-b). Response in RHR and step count is more pronounced for an individual reporting persistent shortness of breath and fatigue (c-d). Both participants exhibited reduced step count a day prior to the test and in the following days, with the participant reporting persistent symptoms showing prolonged reduction. (e) Workflow of cohort creation. (f) Full cohort encompassing a positive cohort (COVID - 19[+]) and negative control cohort (COVID - 19[-]). (g) Differentiated cohort encompassing the persistent symptoms cohort (COVID - 19[+]PS), the positive control cohort (COVID - 19[+]NS), and the negative control cohort (COVID - 19[-]). (h) Matched cohort consisting of the persistent symptoms match cohort (M - COVID - 19[+]PS), the positive match cohort (M - COVID - 19[+]NS) and the negative match cohort (M - COVID - 19[-]).

9 IO

(1:3)

n = 150

(1:3)

n = 150

n = 50

by 19.53% (SE = 0.46%) of individuals in COVID - 19[-]. Fatigue was reported significantly more 93

often in COVID - 19[+] than in COVID - 19[-] for at least 6 weeks starting from the week of the 94 reported SARS-CoV-2 test, Fig. 2a. Shortness of breath was reported by up to 13.55% (SE = 0.51%) 95 and 2.46% (SE = 0.23%) by individuals in COVID - 19[+] and COVID - 19[-], respectively. It was 96 increasingly reported for 15 weeks in COVID - 19[+] (Fig. 2b). The combination of both symptoms 97 was reported by up to 12.2% (SE = 0.09%) and 1.84% (SE = 0.05%) by individuals in COVID - 19[+]98 and COVID - 19[-] and at increased frequency in COVID - 19[+] for a minimum of 11 weeks, see 99 Fig. 2c. 100

Both, shortness of breath and fatigue, are potentially long lasting symptoms that could help identify 101 individuals suffering from PCC [2, 25, 26]. Other assessed symptoms (cough, chills, loss of smell/taste, 102 fever, diarrhea, limb ache and runny nose) did not significantly persist beyond the sub-acute phase 103 when comparing COVID - 19[+] with COVID - 19[-] (Supplementary Figure 1). 104

105

0¹-10

-1 Ò

Based on these findings, we defined a subset of COVID - 19[+] as those individuals who reported 106 shortness of breath and fatigue on at least 5 occasions from the week of the reported positive SARS-107 CoV-2 test (COVID - 19[+]PS). Individuals in COVID - 19[+]PS reported on average 6.2 (Std 108 = 2.33, SE = 0.2) unique symptoms during the acute phase compared to 2.41 (Std = 2.39, SE = 109 (0.01) symptoms reported by individuals with a positive SARS-CoV-2 test but no persistent symptoms 110

All rights reserved. No reuse allowed without permission.

Table 1.	Characterization	of the study	cohorts as	defined i	in Fig. 1.	For additiona	l information on
the report	ed health states 1	per cohort, se	e Tab. S1.				

	COVID-19	COVID-19	COVID-19	COVID-19	M-COVID-19	M-COVID-19	M-COVID-19
	$[+]^1$	[-]	$[+]NS^2$	$[+]PS^{3}$	[-]	$[+]NS^4$	[+]PS ⁵
Ν	7,691	12,987	$7,\!669$	137	150	150	50
Vaccinated [%]	90.0***	88.3	90.0^{***}	88.3	91.3	90.0	88.0
Not vaccinated [%]	0.4	0.5	0.4	0.7	0.0	0.0	2.0
Mean Age	52.4^{***}	55.0	52.4^{***}	52.7	53.6	53.6	53.6
(Std)	(11.9)	(12.0)	(11.9)	(11.7)	(10.5)	(10.5)	(10.5)
Female [%]	36.1^{**}	34.1	35.9^{**}	47.4**	50.0	50.0	50.0
Male [%]	54.4	54.7	54.7	40.1^{**}	40.0	40.0	40.0
Unspecified [%]	9.8^{***}	11.9	9.8^{***}	11.7	10.0	10.0	10.0
Mean BMI	26.2	26.5	26.2	27.7^{*}	26.9	25.5	27.4
(Std)	(4.7)	(5.1)	(4.7)	(5.7)	(6.2)	(4.0)	(4.6)
-					0		

1 COVID - 19[+] vs. COVID - 19[-]; 2 COVID - 19[+]NS vs. COVID - 19[-]; 3 COVID - 19[+]PS vs.

 $COVID - 19[+]NS; {}^{4}M - COVID - 19[+]NS$ vs. $\dot{M} - COVID - 19[-]; {}^{5}M - COVID - 19[+]PS$ vs.

M - COVID - 19[+]NS. p-values: *p < 0.05, **p < 0.01, ***p < 0.001.



Fig 2. Relative frequency of self-reported fatigue (a), shortness of breath (b), and their combination (c), all relative to the week of the reported SARS-CoV-2 test for positive (P) individuals and a matched negative control (NC) cohort. Shading indicates the 99% confidence interval, i.e, 2.576 times the standard error of a binomial distribution. Asterisks indicate significant differences between the cohorts using a two-sided two proportion z-test with a significance level of 0.01.

111 (COVID-19[+]NS) and 0.59 (Std = 1.14, SE = 0.00) symptoms reported by individuals in COVID-112 19[-] (Supplementary Figure 2).

Supplementary Figure 3 illustrates relative frequencies of all symptoms in all phases, relative to the test date window for all cohorts, comprehensively.

¹¹⁵ Persistent symptoms correspond to more pronounced and prolonged RHR-changes

We analyzed wearable-derived data around the SARS-CoV-2 test (Fig.3) for the three age- and gendermatched (1:3) cohorts: M - COVID - 19[+]PS, M - COVID - 19[+]NS and M - COVID - 19[-](Fig.1h).

All rights reserved. No reuse allowed without permission.

To assess differences in RHR, we computed the average RHR for each individual over the last seven days, obtaining one data point per day relative to the test date. We adjusted for seasonal differences by subtracting the daily mean RHR of the CDA population (see Supplementary Figure 4a for seasonal differences in RHR).

To standardize the data and ensure comparability between individuals, we calculated per-user zscores by subtracting each user's average RHR and dividing by the standard deviation in the seven days prior to a reported SARS-CoV-2 test. This normalization centers all time series around zero, measured in units of standard deviation. We then averaged these Z-scores across all individuals within each cohort (see Methods for details).

128

154

¹²⁹ We observed distinct RHR regulation patterns between the cohorts (Fig. 3 a). Individuals in ¹³⁰ M - COVID - 19[+]NS and M - COVID - 19[-] had comparable levels of mean RHR except during ¹³¹ the acute phase.

The minimum Z-score during the acute phase for the M - COVID - 19[+]PS cohort was -0.86, 132 compared to -0.45 for the M - COVID - 19[+]NS cohort, indicating that the average RHR in the 133 M - COVID - 19[+]PS cohort was 0.86 standard deviations below the pre-phase mean, compared to 134 0.45 standard deviations for the M - COVID - 19[+]NS cohort. The range between the maximum 135 and minimum deviation in the period 14 days before to 20 days after the test was more pronounced 136 for the M - COVID - 19[+]PS cohort, with a factor difference of 1.3 in the corresponding z-scores. 137 In addition, M - COVID - 19[+]PS individuals had a transient tachycardia followed by prolonged 138 relative bradycardia, that did not return to baseline (z-score ≥ 0) until 18 days after infection. The 139 relative bradycardia of M - COVID - 19[+]NS individuals persisted until 15 days after infection. 140 Notably, M - COVID - 19[+]PS individuals have on average an elevated RHR compared to the 141

141 Notably, M = COVID - 19[+]PS individuals have on average an elevated KHK compared to the 142 two control cohorts already *prior* to the reported SARS-CoV-2 test (inset in Fig.3a). Specifically, 143 M - COVID - 19[+]PS individuals exhibited an average increase of 2.37 bpm and 1.49 (between 21 144 to 7 days to the test) compared to M - COVID - 19[+]NS and M - COVID - 19[-] individuals, 145 respectively.

¹⁴⁶ Physical activity profiles in acute and sub-acute infection regulation

To assess differences in physical activity patterns between individuals in the M - COVID - 19[+]PS, M - COVID - 19[+]NS, and M - COVID - 19[-] cohorts, we analyzed the average step count per user per day in the pre-, acute-, sub-acute and post-phase of the *match cohort* (Fig. 3b). Seasonal differences in activity (i.e., higher and lower step count during summer and winter, respectively, see (Supplementary Figure 4b)), were accounted for by subtracting the average of all participants in the CDA population from the average steps per day, see Methods Section for details. Results are presented relative to the mean steps per day during pre-phase of the M - COVID - 19[-] cohort.

The respective median step count for M - COVID - 19[+]PS-individuals was consistently below 155 the median of both control cohorts in all four phases. Although the three cohorts are age- and sex-156 matched, the lower step counts in the M - COVID - 19[+]PS cohort may reflect reduced activity 157 levels. The mean step count per day was also below the mean step count of the two control cohorts 158 in all four phases. During the pre-phase, the mean step count of the M - COVID - 19[+]PS cohort 159 was 3,030 steps less than that of the M - COVID - 19[+]NS cohort and 2,909 steps less than the 160 M - COVID - 19[-] cohort. This indicates a generally lower level of activity compared to individuals 161 from the M-COVID-19[+]NS and M-COVID-19[-] cohort. In addition, M-COVID-19[+]PS162 individuals engaged at least three weeks prior to the infection in 1.12 and 0.99 days of high physical 163 activity less than individuals from the M - COVID - 19[+]NS and M - COVID - 19[-] cohorts, 164 respectively (Supplementary Figure 5). 165

¹⁶⁶ Persistent symptoms relate to lower well-being and quality of life

¹⁶⁷ To explore the relationship between wearable data characteristics and perceived well-being and QoL, ¹⁶⁸ we analyzed responses to an adapted version of the WHO-5 wellbeing index [27], [28] and a modified

All rights reserved. No reuse allowed without permission.



Fig 3. Wearable data analysis of the *match cohort*. (a) Z-transformed mean RHR (average of all 15-minute RHR measurements within the last seven days) relative to the seasonal mean RHR with respect to the mean and standard deviation up to seven days prior to the date of the reported test of all individuals in the M - COVID - 19[+]PS (pink), M - COVID - 19[+]NS (blue) and M - COVID - 19[-] (black) cohorts. The difference between the maximum and minimum z-transformed RHR within 14 to and 20 days after the date of the reported SARS-CoV-2 test was more pronounced (1.3 vs 1.0) and more prolonged for M - COVID - 19[+]PS than for M - COVID - 19[+]NS. Shading indicates standard errors. The inset shows the average RHR relative to the SARS-CoV-2 test date. Already prior to the SARS-CoV-2 test, M - COVID - 19[+]PS-individuals showed an increased RHR compared to M - COVID - 19[+]NS and M - COVID - 19[-]. (b) Average steps per day relative to the mean of M - COVID - 19[-] during pre-phase (adjusted for seasonal variation) in all four phases for all individuals in all three cohorts. Boxes indicate quartiles, whiskers the range of the distribution of mean steps per day, scatter points outside the boxes mark the outliers (we do not show outliers > 20ksteps per day), and scatter points within the box mark the mean. The dashed grey line indicates the median of the mean steps per day during the pre-phase. Median values for M - COVID - 19[+]PSwere consistently below the seasonal mean of the CDA population and below the median of the two control cohorts across all phases, indicating lower activity levels compared to the control cohorts. Mean number of steps per day for M - COVID - 19[+]PS were below the mean number of steps per day of the two control cohorts in all four phases. Likewise we found a reduction in the variance of the M - COVID - 19[+]PS compared to the two control cohorts.

All rights reserved. No reuse allowed without permission.

EQ-5D health-related QoL survey (see SI for details) across the *differentiated cohort* (Fig. 1g), see Fig. 4 Due to the timing of the EQ-5D administration (post-2022), responses were not differentiated by pre- or post-SARS-CoV-2 test periods. By then, most participants had already reported a test (see

172 173 Supplementary Figure 8).

Our version of the WHO-5 wellbeing index is constructed from five questions rated on a five-point 174 scale (ranging from never (1) to always (5), with (3) is neutral; see SI for details). We examined the 175 response for each individual question as well as the average response (Fig. 4 a, c-g). The overall distri-176 bution of wellbeing in COVID - 19[+]PS was skewed towards low values, (Fig. 4a) with a mean value 177 of 2.62 (Std = 0.55, SE = 0.05) for the COVID - 19[+]PS cohort and a mean of 3.22 (Std = 0.63, 178 SE = 0.01) and 3.2 (Std = 0.69, SE = 0.01) for the COVID - 19[+]NS and COVID - 19[-] cohort, 179 respectively. We also observed lower wellbeing scores for all individual outcomes (Fig. 4 c-g). Users in 180 COVID - 19[+]PS reported particularly low scores for feeling energetic and rested upon waking up 181 (Fig. 4d), possibly indicating activity and sleep issues. Statistically significant differences ($\alpha = 0.001$) 182 between the COVID-19[+]PS and the control cohorts were found in regards to all WHO-5 questions, 183 as determined by the Mann-Whitney U test. Likewise, we found statistically significant differences be-184 tween the reports of the two control cohorts except for the questions "In the past four weeks I felt fresh 185 and rested when waking up" (d), "In the past four weeks I was calm and relaxed" (g), and the mean of 186 wellbeing. We observed statistically significant differences between all three cohorts, nevertheless the 187 significance level (p-value) was lower when comparing the COVID - 19[+]PS cohort to the control 188 cohorts than for the intra-control cohort comparison. 189

190

In addition, we examined EQ-5D health-related QoL assessed by five questions answered on an 191 ordinal scale ranging from the best ("I have no problems/No"; coded as 5) to the worst outcome ("I am 192 not able to do that/extreme"; coded as 1) (Fig. 4b, h-l). The average response to the five questions, a 193 measure of overall QoL, was systematically lower for individuals in COVID - 19[+]PS compared to 194 the control cohorts (Fig. 4p) with a mean of 2.79 (Std = 0.62, SE = 0.06). Again, COVID - 19[+]NS195 and COVID - 19[-] show similar values across modified EQ-5D questions and overall with a mean 196 of 3.55 (Std = 0.46, SE = 0.01) and 3.52 (Std = 0.52, SE = 0.01) for COVID - 19[+]NS and 197 COVID - 19[-], respectively. Likewise, COVID - 19[+]PS-individuals reported lower QoL across 198 all five questions (Fig. 4h-l) compared to the control cohorts, particularly concerning problems moving 199 around and pain and physical symptoms (Fig. 4 b and k), again possibly indicating the presence of 200 comorbidities or pre-existing conditions. 201

The answers of the COVID - 19[+]PS cohort were significantly different from the control cohorts for all QoL questions ($\alpha = 0.001$). Notably, also the answers of the COVID - 19[+]NS compared to the COVID - 19[-] cohort were significantly different except for the the mean of QoL (b) and the question "Do you have problems moving around?" (h), and "Do you have problems when it comes to general activities (work, studying, housework, family- or leisure activities)?" (j). However, the significance level was again lower when comparing the COVID - 19[+]PS cohort to the two control cohorts than for the intra-control cohort comparison.

209

We also analyzed the responses to the wellbeing and QoL questions before (Supplementary Figure 6) and after (Supplementary Figure 7) the reported SARS-CoV-2 tests and found systematically lower values of wellbeing and QoL for the COVID - 19[+]PS cohort before as well as after the reported test compared to the COVID - 19[+]NS and COVID - 19[-] cohorts. This suggests that individuals with lower levels in wellbeing and QoL may be at higher risk of developing long-term symptoms, possibly due to pre-existing general physical or mental health problems that may be related to another underlying condition.

217

In addition, we performed simple logistic regression analysis to identify characteristics that might serve as predictors of the development of persistent symptoms. Given the imbalance between the M - COVID - 19[+]PS and M - COVID - 19[+]NS cohorts, we focused on the area under the precisionrecall curve (AUPRC). Using 10-fold cross-validation with stratified sampling, the model achieved an

All rights reserved. No reuse allowed without permission.



Fig 4. WHO-5 wellbeing (a,c-g) and modified EQ-5D/QoL (b,h-l) for the COVID - 19[+]PS (pink), COVID - 19[+]NS (blue), and COVID - 19[-] (black) cohorts. The individual WHO-5 and modified EQ-5D scores were both averaged to obtain the overall wellbeing (a) and QoL (b) scores, respectively. Overall, COVID - 19[+]PS individuals reported more issues with wellbeing (c-g) and QoL (h-l) than the control cohorts. Error bars indicate standard errors. The responses from all COVID - 19[+]PS cohort were significantly different ($\alpha < 0.001$) from the responses of the two control cohorts, as determined by the Mann-Whitney U test. All responses of the two control cohorts were significantly different as well except for the mean value of wellbeing (a), the mean value of QoL (b), and the questions "In the last four weeks I was calm and relaxed" (g) and "Do you have problems going around" (h).

All rights reserved. No reuse allowed without permission.

AUPRC of 0.75, indicating moderate predictive performance. Feature importance analysis, based on 222 mean coefficients and odds ratios across cross-validation folds, identified number of unique symptoms 223 reported during the acute-phase of infection, chronic bronchitis, unspecified sex, and allergies as the 224 most influential features, with mean odds ratios (OR) of 4.40, 1.65, 1.53, and 1.35, respectively. Mean 225 pre-infection RHR also emerged as a notable predictor, with a mean OR of 1.31. These findings suggest 226 that integrating wearable-derived data such as RHR with traditional clinical variables can enhance the 227 identification of individuals at higher risk of developing persistent symptoms. This highlights the 228 potential value of wearable technology in supplementing conventional approaches for early detection 229 and management of PCC. 230

Table 2. Predictive features for developing long COVID based on logistic regression analysis. The table shows the mean coefficients, standard deviations, and mean odds ratios from 10-fold cross-validation.

Feature	Mean Coefficient	Std Coefficient	Mean Odds Ratio
Number of Symptoms	1.482	0.119	4.40
Chronic Bronchitis	0.498	0.089	1.65
Gender (Unspecified)	0.427	0.178	1.53
Allergies	0.298	0.135	1.35
Mean RHR Pre-Phase	0.273	0.149	1.31
Mental Health Condition	0.260	0.109	1.29
Age	0.142	0.152	1.15
Gender (Male)	0.058	0.157	1.06
Steps During Acute Phase	0.058	0.161	1.06
Asthma	0.053	0.103	1.05
Increased Blood Lipids/Cholesterol	-0.030	0.084	0.97
Other Conditions	-0.075	0.076	0.93
No Disease	-0.078	0.163	0.93
Hypertensive Disease	-0.226	0.132	0.80
Mean RHR Acute-Phase	-0.372	0.179	0.69
Gender (Female)	-0.485	0.123	0.62
Mean Steps per Day Pre-Infection	-0.750	0.143	0.47
WHO-5 Wellbeing Score	-1.038	0.115	0.35

231 Discussion

Our study comprehensively characterizes how persistent self-reported symptoms in acute and post-232 acute COVID-19 infection relate to changes in resting heart rate and physical activity measured by 233 consumer grade wearable sensors. This observational study provides a descriptive analysis of the 234 variation in heart rate, physical activity, and self-reported health status among different cohorts, and 235 highlights patterns that may be linked to persistent symptoms following SARS-CoV-2 infection. Based 236 on RHR, step count, and survey-based QoL, we identified patterns associated with a phenotype of per-237 sistent COVID-19 symptoms compared to COVID-19 positive and negative controls. Individuals with 238 this phenotype are characterized by persistent (sub-acute and post-phase) shortness of breath and 239 fatigue, and tended to have elevated RHR levels and less physical activity *prior* to infection, as well 240 as, on average, lower well-being and health-related QoL scores compared with positive and negative 241 controls. 242

We found notable differences in the prevalence of fatigue, shortness of breath, and their co-244 occurrence in SARS-CoV-2 positive and negative individuals. Both symptoms have been reported 245 as typical, persistent symptoms of COVID-19 which are common in individuals with PCC 2, 5, 6, 29. 246 Indeed, according to a WHO case definition, fatigue and dyspnoea (shortness of breath) are the main 247 symptoms of PCC 30. Our analysis confirmed that these symptoms were significantly more frequent 248 in the positive cohort than in the controls, with a marked persistence beyond the acute phase. Other 249 symptoms did not show the same prolonged pattern, highlighting the specificity of these particular 250 symptoms in relation to PCC. 251

A comparison of the wearable data (RHR and step count) revealed that during the acute phase (0-4 weeks after positive SARS-CoV-2 test) of COVID-19, individuals who reported persistent symptoms exhibited (1) higher RHR before infection, (2) on average more pronounced bradycardia up to

²⁴³

All rights reserved. No reuse allowed without permission.

18 days after the positive SARS-CoV-2 test, and (3) lower physical activity before during and after in-255 fection compared to positive controls. Similar differences have been observed in previous studies when 256 comparing SARS-CoV-2 positive and negative individuals [13, [14]. Individuals that later reported 257 persistent symptoms already exhibited an elevated average RHR (mean increase of 2.37 bpm/1.49 258 bpm) compared to positive/negative control cohorts prior to their SARS-CoV-2 testing. In addition, 259 these individuals were less likely to engage in high-intensity activities (i.e. regular physical activity 260 and/or training) and were generally less active than the two control cohorts. Specifically, their daily 261 step count was on average 3,030/2,909 steps less and they engaged in high activity 1.12/0.99 days 262 less during the pre-phase than the positive/negative controls. Given the known inverse relationship 263 between RHR and physical activity 31, 32, these patterns suggest that lower physical fitness levels. 264 possibly due to pre-existing conditions, could increase susceptibility to developing long-term symptoms. 265 266

When comparing the COVID - 19[+] and COVID - 19[-] cohorts and the COVID - 19[+]NSand COVID - 19[-] cohorts, we found significantly higher reported vaccination rates in the positive cohorts, but no significant difference in the proportion reporting no vaccination. This suggests that the observed difference in vaccination rates may be due to reporting bias rather than actual differences in health status.

The positive cohorts (COVID - 19[+] and COVID - 19[+]NS) were also generally younger than the negative cohort (COVID - 19[-]). This age difference may lead to an underestimation of our results. There were also fewer individuals in the negative cohort who reported their gender, suggesting a potential reporting bias.

When comparing the COVID - 19[+]PS (persistent symptoms) and COVID - 19[+]NS (no persistent symptoms) cohorts, we observed a significantly higher proportion of women in the persistent symptom group, suggesting an association between female gender and the development of persistent symptoms, consistent with the existing literature [4], [33].

We observed a significantly higher BMI in the COVID-19[+]PS cohort compared to the COVID-19[+]NS cohort. While this suggests that individuals with persistent symptoms (COVID-19[+]PS) may have a higher BMI, it is important to note that the number of participants who provided both weight and height information was too small to reliably include BMI in the logistic regression analysis.

The COVID - 19[-] cohort reported fewer cases of "no disease in the past 12 months," indicating more comorbidities compared to the positive cohorts. They had higher rates of conditions such as hypertension, elevated cholesterol, chronic bronchitis, and mental health diagnoses. This suggests that the negative cohort may be less healthy overall, which may cause our results to represent a lower bound of the true effect, as the negative cohort may be less healthy overall.

When comparing the COVID - 19[+]PS cohort to the COVID - 19[+]NS cohort, the COVID -289 19[+]PS group reported more allergies, asthma, chronic bronchitis, mental illness, and "other con-290 ditions". This suggests a higher burden of comorbidities among those with persistent symptoms. 291 Similarly, in the matched cohorts (M - COVID - 19[+]PS vs. M - COVID - 19[+]NS), the 292 M - COVID - 19[+]PS cohort had higher rates of allergies, chronic bronchitis, and mental illness, 293 supporting the notion that pre-existing health conditions may play a role in the development of per-294 sistent symptoms. This is in line with findings on the association of these conditions and the risk of 295 developing PCC 34, 35. 296

297

It is important to note that our findings should not be interpreted in a way that increased RHR, lower step count, and pre-existing health conditions solely determine the manifestation of persistent symptoms. Instead they emphasize that individuals displaying these characteristics should be given extra attention and protection measures.

302

Our analysis of self-reported well-being and QoL showed significantly lower levels for individuals with persistent symptoms compared to the control cohorts, both before and after the reported SARS-CoV-2 test. This suggests the possibility of underlying physical or mental health problems, such as chronic conditions or allergies (see Supplemetary Table 1), that may predispose individuals to persistent symptoms. Specifically we find a mean difference of 0.6/0.58 in mean well-being score and a

All rights reserved. No reuse allowed without permission.

mean difference of 0.76/0.73 between COVID - 19[+]PS and COVID - 19[+]NS/COVID - 19[-]individuals. This is in line with recent findings, where individuals reporting persistent symptoms also reported poorer mental health in comparison to a control group [36], as well as a study reporting disturbed sleep as an important risk factor for PCC [37].

312

In addition to our descriptive study, we analyzed the importance of variables associated with the risk of developing persistent symptoms in a predictive model. We found that the number of symptoms during the acute infection phase, chronic bronchitis, unspecified sex, allergies, and mean pre-infection RHR were among the most influential factors. Wearable-derived data may thus complement previously identified risk factors for the development of persistent symptoms [38, 39].

While "unspecified gender" emerged as a risk factor, this likely reflects differences in reporting behavior rather than biological risk. Individuals who do not report gender may differ in unmeasured characteristics, such as privacy concerns or health-seeking behaviors, that affect symptom reporting or health outcomes. Thus, this finding should be interpreted with caution, as it may reflect data completeness issues or participant behavior rather than a direct risk for developing persistent symptoms.

The use of wearable data allows detailed examination of activity and heart rate patterns, provid-324 ing insight not only into how SARS-CoV-2 infection may affect behavior and physiology in the long 325 term, but also into the health status of individuals prior to contracting the disease. The data provides 326 distinct advantages for evaluating the general health state of individuals holistically, continuous, under 327 natural conditions, and outside of healthcare facilities [40, 41]. Wearables thus have the potential to 328 improve patient-centered care by empowering individuals to monitor their health and manage their 329 symptoms more effectively [42, 43]. In addition, data donation projects allow us to investigate individ-330 uals across a broad spectrum of SARS-CoV-2 infection severity, since participants enter the study prior 331 to an infection. This approach enables us to establish a healthy state baseline, based on measurements 332 prior to an infection, for individuals without biasing the study towards specific infection severities. In 333 other words, participants are not selectively enrolled into the study based on their expected severity 334 of subsequent SARS-CoV-2 infection symptoms or outcomes. This is of particular significance in the 335 context of PCC research, since this condition is not exclusively linked to severe COVID-19 cases [44]. 336 337

Several factors should be considered when interpreting our results. The Corona Data Donation 338 Project had an overrepresentation of males and an underrepresentation of adolescents and the elderly 339 (65+), who are at higher risk for long-term consequences of SARS-CoV-2 [13] [45]. The study population 340 is likely to be more health-conscious than the general population because of the association of wearable 341 device use with health-related habits [46]. We did not explicitly account for vaccination status, as most 342 participants are partially vaccinated or did not report their status (see Table 1). This, along with other 343 cohort-specific characteristics, highlights the need to interpret our findings in the context of our study 344 population, which may not be fully generalizable to other groups. We also did not differentiate between 345 variants of concern (VoC), which may trigger different immune responses and heart rate regulation. 346 However, most participants reported their SARS-CoV-2 test date in 2022, when the Omicron variant 347 (B.1.1.529) was dominant in Germany. 348

Keeping all these considerations in mind, it is reasonable to assume that our results under-represent the true disease burden of persistent symptoms and rather provide a lower bound for expected longterm imprints of an infection 36, 47–50. We also did not control for wear time, but Supplementary Figure 9 shows similar distributions across cohorts.

The sample size of the study is limited by the requirement for sufficient wearable data (at least 100 353 heart rate measurements) in all four phases (pre, acute, sub-acute, and post) around a SARS-CoV-2 354 test. We also used strict criteria for defining persistent symptoms (at least five cases of shortness of 355 breath and fatigue after the test), focusing on the most common symptoms observed in PCC [5+7]356 29, 30. While this focused approach inevitably introduces a degree of selection bias by targeting a 357 specific subset of individuals with persistent symptoms, it is critical for accurately identifying those 358 who are clearly affected and understanding their unique health profiles. We recognize that this targeted 359 selection may limit the generalizability of our findings to broader populations. However, it allows for 360

All rights reserved. No reuse allowed without permission.

a more precise examination of the physiological and behavioral characteristics unique to those with
 persistent symptoms, thereby increasing the relevance and specificity of our findings.

The two cohorts studied for symptom reporting are not matched by age and gender, only by calendar week and time relative to a SARS-CoV-2 test. The small differences in age (2.6 years) and gender (1.5%) distributions between these cohorts are unlikely to affect the results(Table 1). Previous studies have found gender differences in symptoms only after the reported SARS-CoV-2 test for symptoms not included in our study 5.

Further studies are needed on the use of wearables to monitor physiological parameters and activity 369 levels over time in individuals with PCC. Particularly, focusing on other persistent symptoms apart 370 from shortness of breath and fatigue can aid in recognizing different patterns of symptom progression 371 and immune response triggers. Moreover, high-frequency heart rate and activity can potentially be 372 relevant for studying postural orthostatic tachycardia syndrome (POTS), a potential consequence of 373 an infection with SARS-CoV-2 and a likely criterion for identifying PCC [51, 52]. Further combination 374 of survey and wearable data would provide a deeper understanding of the relationship between subjec-375 tive symptom reports and objective wearable data, allowing physiological and behavioural measures to 376 be properly translated into experienced alterations to patients' everyday lives. Further integration of 377 wearable technology with telemedicine platforms facilitating the monitoring of symptoms in real-time 378 and enabling remote consultation with healthcare professionals for individuals suffering from PCC can 379 benefit patients and ease the burden on healthcare providers. 380

381

368

The unique advantage of wearable technologies is that continuous real-time data can be collected cheaply and on a large scale to provide fine-grained information on individual health, which is an ideal complement to traditional point-wise measurements in clinical research.

385 Methods

386 Data Characteristics

From April 12, 2020, to December 31, 2022, a total of 535,556 individuals downloaded and used the Corona-Datenspende App (CDA) 23, actively contributing a minimum of one essential data point each. The wearable data, i.e. RHR and step count, was submitted by linking the the app with consumer-grade smartwatches and fitness trackers. Participants could additionally consent to engage in periodic surveys on matters related to COVID-19, e.g., test results, weekly symptoms and monthly questions on QoL.

Weekly symptom reports were collected starting from October 21, 2021. By November 9, 2022, 394 35,355 individuals had participated in at least one survey. Participants could choose to report no 395 symptoms or select one or more symptoms from a predefined list: Shortness of Breath, Fatigue, 396 Headache, Sore Throat, Loss of Smell and Taste, Diarrhea, Runny Nose, Cough, Chills, Limb Ache, 397 and Fever.

Comparisons were made between individuals who reported a positive SARS-CoV-2 test (COVID-398 19[+] = 7,691 individuals) and a negative control cohort (COVID - 19[-] = 12,987 individuals) (see 399 Methods and Fig. [1e]. Participants in the COVID - 19[+] cohort reported symptoms an average of 400 18.4 times (standard deviation (Std) = 11.2). Participants in the NC cohort submitted reports 11.1 401 times on average (Std = 11.4). The COVID - 19[+] cohort was further split in sub-cohorts, one with 402 individuals that reported persistent symptoms (COVID - 19[+]PS = 137 individuals) and the rest 403 (COVID - 19[+]NS = 7669 individuals), which together with the COVID - 19[-] cohort yielding 404 in three cohorts, see Methods and Fig. 1e) for details on cohort creation. 405

406

For these cohorts we analysed survey responses on wellbeing and QoL. The questions on WHO-5 well-being were distributed since October 2021 and rolled out together with the symptom surveys. 35,492 individuals submitted corresponding answers. Particularly, all 137 individuals reporting persistent symptoms, 7,609 individuals from the COVID - 19[+]NS cohort and 12,866 users from the COVID - 19[-] cohort answered the survey on well-being at least once. The WHO-5 wellbeing index

All rights reserved. No reuse allowed without permission.

⁴¹² [27], [28] is answered on a six-point scale ranging from never(0) to always (5). For technical reasons the ⁴¹³ CDA uses a slightly altered version that utilizes a five-point scale ranging from 1 to 5 with 3 being ⁴¹⁴ neutral. The five questions ask: 'In the past four weeks I was happy and in a good mood.', '... I felt ⁴¹⁵ calm and relaxed.', '... I felt energetic and active.', '... I felt fresh and rested when waking up.', and ⁴¹⁶ '... my everyday life was full of things that interest me.'

The modified EQ-5D survey on QoL was distributed since April 2022 to 12,179 participants. 92 417 individuals with persistent symptoms, 2,647 from the COVID-19[+]NS cohort and 12,866 individuals 418 from the COVID - 19[-] cohort answered the five questions on QoL a least once. The survey asks to 419 indicate what best describes the state of health today: 'Do you have any problems moving around?', 'Do 420 you have any problems taking care of yourself, washing or dressing yourself?', 'Do you have problems 421 when it comes to general activities (work, studying, housework, family- or leisure activities)?', 'Do 422 you have pain/physical symptoms?', and 'Are you anxious or depressed?'. The answers are on an 423 ordinal scale ranging from the best possible outcome ("I have no problems/No"; coded as 5) to the 424 worst possible outcome ("I am not able to do that/extreme"; coded as 1). For three age- and gender 425 matched cohorts (1:3) denoted persistent symptoms match (M - COVID - 19[+]PS = 50), positive 426 match (M - COVID - 19[+]NS = 150) and negative match (M - COVID - 19[-] = 150), we analyzed 427 high frequency longitudinal data on RHR and step count (see Methods and Fig. 1). Data on RHR 428 and step count were collected in intervals as low as 60 seconds. We show four exemplary timeseries 429 spanning three weeks each in Fig. 1a-d. 430

431 Cohort creation

To study reported symptoms relative to a reported positive SARS-CoV-2 test (COVID - 19[+]PS)432 and compared them with a negative control (COVID - 19[-]) cohort we looked at 35,355 individuals 433 who filled out the corresponding surveys. We excluded 3,660 individuals who reported a positive SARS-434 CoV-2 test in a previously distributed one-time questionnaire to avoid previous infections with SARS-435 CoV-2 in the population. We divided the population into two groups: those with at least one positive 436 SARS-CoV-2 test and those with all negative tests. Both cohorts are limited to the period between 437 October 21, 2021, and November 9, 2022. For individuals with positive tests, we used the date of 438 their first positive test if multiple tests were positive. To avoid including individuals with re-infections, 439 we excluded those reporting a test more than 28 days after the chosen test date, resulting in 7839 440 individuals. Among the 18,282 individuals reporting only negative tests, we randomly selected a test 441 date. We also excluded users who reported shortness of breath more than four times before their test 442 result, as a proxy for pre-existing respiratory conditions. To account for seasonal effects in symptom 443 reporting, we adjusted the negative cohort to match the relative frequency of negative reports per 444 calendar week and the temporal distance to the test week observed in the positive cohort. This yields 445 a positive cohort (COVID - 19[+]NS) of 7,691 individuals and a negative control (COVID - 19[-])446 of 12,987 individuals (full cohort, Fig. 1f). 447

For the analysis of WHO-5 and modified EQ-5D, we selected individuals from COVID - 19[+] who reported both shortness of breath and fatigue at least five times after their positive SARS-CoV-2 test. This subset, comprising 137 individuals, forms the persistent symptoms cohort (COVID - 19[+]PS). We compared their survey responses with those of the remaining 7,669 individuals in the Positive Cohort (referred to as the positive control cohort (COVID - 19[+]NS)) and the 12,987 individuals from the negative control (COVID - 19[-]) cohort (differentiated cohort Fig. 1g).

To study differences and changes in physiological parameters (RHR) and behavior (step count) 454 between the COVID - 19[+]NS, COVID - 19[-], and COVID - 19[+]PS cohorts, we analyzed 455 fine-grained wearable data collected by wearable devices. We standardized the data by aggregating 456 high-frequency measurements into 15-minute intervals. Four phases relative to the reported SARS-457 CoV-2 test are defined: pre-phase (start of data collection until the week of the positive test), acute 458 phase (zero to four weeks after the test), sub-acute phase (five to twelve weeks), and post-phase (twelve 459 weeks or more after the positive test), aligning with recent definitions of COVID-19 disease stages 24. 460 After excluding individuals with less than 100 15-minute interval heart rate measurements across all 461 phases, the persistent symptoms match (M - COVID - 19[+]PS) cohort comprises 50 individuals. 462 We created (1:3) age- and gender-matched positive match (M - COVID - 19[+]NS) and negative 463

All rights reserved. No reuse allowed without permission.

match (M - COVID - 19[-]) cohorts, each with 150 individuals selected from the COVID - 19[+]NSand COVID - 19[-] cohorts, respectively (match cohort, Fig. [h). We chose a 1:3 matching, common in medical research, to increase statistical power and to improve the generalizability of our findings by ensuring that the control group more accurately represents the population from which the cases and controls were drawn.

 $_{469}$ For characteristics of the cohorts see Tabs. $\boxed{1}$ and S1.

470 Data processing and statistical analysis

471 Statistical analysis of group differences.

To analyze group differences in our study cohorts, we used different statistical tests tailored to the nature of the data. Continuous variables, such as age and BMI, were analyzed using the Kruskal-Wallis test. Categorical variables, including sex, vaccination status, and comorbidities, were assessed using Fisher's exact test.

We performed these comparisons in three main cohort analysis: In the *full cohort* analysis, we 476 compared the positive and negative cohorts (COVID-19[+] vs. COVID-19[-]). In the differentiated 477 cohort analysis, we compared the positive without persistent symptoms cohort and the negative cohort 478 (COVID-19[+]NS vs. COVID-19[-]) as well as the positive with persistent symptoms cohort and 479 the positive without persistent symptoms cohort (COVID - 19[+]PS vs. COVID - 19[+]NS). In 480 the *matched cohort* analysis, we compared differences between the matched positive without persistent 481 symptoms cohort and the matched negative cohort (M - COVID - 19[+]NS vs. M - COVID - 19[-])482 and the matched positive with persistent symptoms cohort and the matched positive without persistent 483 symptoms cohort (M - COVID - 19[+]PS vs. M - COVID - 19[+]NS). 484

For all statistical tests, significance levels were set at three thresholds: $\alpha = 0.05$, $\alpha = 0.01$, and $\alpha = 0.001$.

⁴⁸⁷ Weekly reports on symptoms.

For the COVID - 19[+] and the COVID - 19[-] cohorts, we compared the relative frequency of symptom reports relative to the calendar week in which a SARS-CoV-2 test was reported. We detected differences between the two groups at 99% confidence using a two-sided two proportion z-test and a significance level of 0.01. To investigate whether pairs of symptoms are significantly concordant, we compared the relative frequency of reports where individuals report both symptoms.

⁴⁹³ Resting heart rate and step count.

To ensure data consistency, we only analyzed one source/device per participant (e.g., Apple Health, 494 Fitbit, or Garmin). If a user has multiple devices, we prioritized the one with the most data points, 495 potentially leading to missing information if different devices are used for different activities. Observa-496 tions are based on measurement intervals ranging from less than one minute to several hours, resulting 497 in overlapping intervals in a few instances and a slight overestimation of daily activity. This is rare 498 compared to the total data volume. In our data pre-processing approach, intervals longer than one 499 minute were split into one-minute segments and duplicate intervals are removed. These one-minute 500 intervals were then resampled to 15-minute intervals by calculating the mean of the RHRs and the 501 sum of the steps. In cases where a user contributes data from multiple sources, only the source with 502 the highest number of entries is considered. 503

To compare RHRs between the M - COVID - 19[+]PS cohort, the M - COVID - 19[+]NS504 cohort and the M - COVID - 19[-] cohort, for each user and each day we first computed (relative 505 to the reported SARS-CoV-2 test) an average of all 15 minute intervals within the past seven days. 506 We only computed the average if there were more than 20 entries within that seven-day window. We 507 then computed the average RHR over all users in a cohort, again relative to the reported SARS-CoV-2 508 test. To evaluate tachycardia during the acute phase of the infection, we z-transformed the average 509 of all 15 minute intervals within the last seven days per user relative to the mean RHR prior to the 510 test (window of 62 days to 7 days before the date of the reported test). We additionally controlled for 511 seasonal fluctuations by z-transforming the average RHR relative to the seasonal mean of the CDA 512 population (Supplementary Figure 4a). 513

To examine differences in behavioral changes around a SARS-CoV-2 infection between cohorts, we investigated the average step count for the cohort members. As the daily step count shows seasonal

All rights reserved. No reuse allowed without permission.

variations 13, we always assessed this metric by subtracting the respective mean value per day and 516 device within the entire set of participants of the whole Corona Data Donation project, see also 517 Supplementary Figure 4b. We show the difference to the mean daily step count (adjusted for seasonal 518 variation) of the M - COVID - 19[-] cohort during pre-phase. A positive/negative value then 519 indicates that an individual is more/less active than the M - COVID - 19[-] cohort during pre-phase 520 average. To assess variations or shifts in high-intensity physical activity, such as sports, we established 521 a criterion where a day is considered to be high-intensity physical activity if the step count is more 522 than one standard deviation above the seasonal average step count. 523

⁵²⁴ Monthly surveys on well-being and quality of life.

For the analysis of the surveys on well-being/QoL we calculated the mean response to each question 525 per user over all answers (not discriminating between before and after day of reported SARS-CoV-2 526 test) and showed the relative frequency of each possible answer value per cohort. Error bars indicate 527 the standard error. The answers to each one of the five WHO-5 Well-Being questions are designed so 528 that they can be averaged to obtain a mean value of well-being. Note, that the WHO-5 well-being 529 is usually measured on a six-point scale. Due to technical reasons however, our survey provides an 530 ordinal five-point scale. This also applies to the five modified EQ-5D QoL questions. The modification 531 is attributed to different translations of questions and answers, along with one missing question. For 532 both the WHO-5 and the modified EQ-5D, we show a histogram of the distribution of the respective 533 mean scores for all three cohorts studied. 534

535 Logistic Regression.

We performed logistic regression analysis to identify variables associated with the risk of developing persistent symptoms after SARS-CoV-2 infection. To ensure robustness, we used 10-fold stratified cross-validation to assess model performance and calculate the area under the precision-recall curve (AUPRC). Feature importance was assessed by calculating mean coefficients, standard deviations and odds ratios across cross-validation folds.

541 Ethical consideration

Participation in the study was voluntary and self-recruited. All individuals participating in the Corona 542 Data Donation Project provided informed consent electronically via the app. Consent was provided 543 separately for submitting wearable data and participating in the in-app surveys. Participation is 544 only possible for German residents age 16 and older and data is only stored pseudonymously, using a 545 randomly generated unique user ID. Participant age is rounded to 5 years. The study is subject to strict 546 compliance with the data protection provisions set out in the EU General Data Protection Regulation 547 (GDPR) and the Federal Data Protection Act (BDSG). A comprehensive privacy impact assessment 548 was conducted through an external law-firm specialized in e-Health and research projects. The study 549 was reviewed and approved by the Data Privacy Officer at the Robert Koch Institute (internal operation 550 number 2021-009) in agreement with the Federal Commissioner for Data Protection and Freedom of 551 Information (BfDI), Germany's highest independent supreme federal authority for data protection and 552 freedom of information. Ethical approval for this study was obtained from the ethics board at the 553 University of Erfurt (approval number 20220414). 554

555 Data availability

The data analyzed in this study concerns the health condition of individual persons. As per the General Data Protection Regulation (GDPR) such data constitutes sensitive information and is protected as a "special category of personal data". For this reason, the data must not be directly shared in a public repository, but interested parties can request access to the data following registration with the Data Privacy Officer at the Robert Koch-Institute. All initial data inquiries should be addressed to Dirk Brockmann (dirk.brockmann@tu-dresden.de) or the general contact address of the Corona Data Donation project (synosys@tu-dresden.de).

⁵⁶³ Code availability

Python 3.11.6 was used to perform the simulations and data analysis. The simulation and analysis code for this study will be available under MIT license in the repository at https://github.com/ katharinaledebur/characteristics_persistent_symptoms.git.

567 Acknowlegdements

This study was financed with funds from the overall funding program of the City of Vienna MA7. Funding was also received from the Federal Ministry of Health of Germany (Grants "Corona-Datenspende", CD21, DS22 and DS23).

571 Author contributions

MW and KL conceptualized the study. MW supervised the project. DB devised and created the Corona 572 Data Donation project. MW and KL devised the analytic methods. KL carried out the analysis and 573 produced the plots and graphics. KL and MW directly accessed and verified the underlying data 574 reported in the manuscript. KL and MW wrote the first draft of the manuscript. CP, DB, ST and PK 575 made critical comments regarding the manuscript. CP contributed medical expertise regarding the 576 medical interpretation of the findings and in developing medical hypotheses. KL, MW, CP, PK, DB 577 and ST conducted reviewing and editing of the manuscript. All authors read and approved the final 578 manuscript. 579

580 Competing interests

581 The authors declare no competing interests.

All rights reserved. No reuse allowed without permission.

582 **References**

- ⁵⁸³ 1. World Health Organization. Post COVID-19 condition (Long COVID) https://www.who.int/
- europe / news room / fact sheets / item / post covid 19 condition# : ~ : text = It%20is% 20defined%20as%20the,months%20with%20no%20other%20explanation.
- Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. en. *Nature Reviews Microbiology* 21, 133-146. ISSN: 1740-1526, 1740-1534.
 https://www.nature.com/articles/s41579-022-00846-2 (Mar. 2023).
- Menges, D. *et al.* Burden of post-COVID-19 syndrome and implications for healthcare service
 planning: A population-based cohort study. en. *PLOS ONE* 16 (ed Simuunza, M. C.) e0254523.
 ISSN: 1932-6203. https://dx.plos.org/10.1371/journal.pone.0254523 (July 2021).
- ⁵⁹² 4. Radin, J. M. *et al.* Long-term changes in wearable sensor data in people with and without Long ⁵⁹³ Covid. *npj digital medicine* (2024).
- 5. Ballering, A. V., Van Zon, S. K. R., Olde Hartman, T. C. & Rosmalen, J. G. M. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. en. *The Lancet* 400, 452-461. ISSN: 01406736. https://linkinghub.elsevier.com/retrieve/pii/
 S0140673622012144 (Aug. 2022).
- Nasserie, T., Hittle, M. & Goodman, S. N. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. en. JAMA Network Open 4, e2111417. ISSN: 2574-3805. https://jamanetwork.com/journals/jamanetworkopen/
 fullarticle/2780376 (May 2021).
- Davis, H. E. *et al.* Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. en. *eClinicalMedicine* 38, 101019. ISSN: 25895370. https://linkinghub.
 elsevier.com/retrieve/pii/S2589537021002996 (2023) (Aug. 2021).
- 8. Marjenberg, Z. *et al.* Risk of long COVID main symptoms after SARS-CoV-2 infection: a systematic review and meta-analysis. *Scientific Reports* **13**, 15332 (2023).
- 9. Høeg, T. B., Ladhani, S. & Prasad, V. How methodological pitfalls have created widespread misunderstanding about long COVID. *BMJ Evidence-Based Medicine* **29**, 142–146 (2023).
- O'Mahoney, L. *et al.* The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. *eClinicalMedicine*55, 101762 (2023).
- Koc, H. C., Xiao, J., Liu, W., Li, Y. & Chen, G. Long COVID and its Management. en. International Journal of Biological Sciences 18, 4768–4780. ISSN: 1449-2288. https://www.ijbs.com/
 v18p4768.htm (2022).
- Han, Q., Zheng, B., Daines, L. & Sheikh, A. Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms. *Pathogens* 11, 269 (2022).
- ⁶¹⁸ 13. Wiedermann, M. *et al.* Evidence for positive long- and short-term effects of vaccinations against
 ⁶¹⁹ COVID-19 in wearable sensor metrics. en. *PNAS Nexus* 2 (ed Levine, B.) pgad223. ISSN: 2752-
- 620 6542. https://academic.oup.com/pnasnexus/article/doi/10.1093/pnasnexus/pgad223/ 621 7225910 (2023) (July 2023).
- Radin, J. M. et al. Assessment of Prolonged Physiological and Behavioral Changes Associated
 With COVID-19 Infection. en. JAMA Network Open 4, e2115959. ISSN: 2574-3805. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2781687 (July 2021).
- Natarajan, A., Su, H.-W. & Heneghan, C. Occurrence of Relative Bradycardia and Relative Tachycardia in Individuals Diagnosed With COVID-19. en. Frontiers in Physiology 13, 898251.
 ISSN: 1664-042X. https://www.frontiersin.org/articles/10.3389/fphys.2022.898251/
 full (May 2022).

- Mishra, T. et al. Pre-symptomatic detection of COVID-19 from smartwatch data. en. Nature
 Biomedical Engineering 4, 1208-1220. ISSN: 2157-846X. https://www.nature.com/articles/
- ⁶³¹ **s**41551-020-00640-6 (2023) (Nov. 2020).
- Gadaleta, M. *et al.* Passive detection of COVID-19 with wearable sensors and explainable machine
 learning algorithms. en. *npj Digital Medicine* 4, 166. ISSN: 2398-6352. https://www.nature.com/
 articles/s41746-021-00533-1 (Dec. 2021).
- ⁶³⁵ 18. Quer, G. et al. Wearable sensor data and self-reported symptoms for COVID-19 detection. en.
- Nature Medicine 27, 73-77. ISSN: 1078-8956, 1546-170X. https://www.nature.com/articles/
 s41591-020-1123-x (Jan. 2021).
- Varsavsky, T. et al. Detecting COVID-19 infection hotspots in England using large-scale selfreported data from a mobile application: a prospective, observational study. en. The Lancet
 Public Health 6, e21-e29. ISSN: 24682667. https://linkinghub.elsevier.com/retrieve/pii/
- 640 Public Health 6, e21–e29. ISSN: 24682667. https://linkinghub.els
 641 \$2468266720302693 (Jan. 2021).
 - Menni, C. *et al.* Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. en. *The Lancet In- fectious Diseases* 21, 939-949. ISSN: 14733099. https://linkinghub.elsevier.com/retrieve/
 pii/S1473309921002243 (July 2021).
 - Robert-Koch Institute. Corona Data Donation Project https://corona-datenspende.github.
 io/en/. Accessed: 2024-09-16.
 - Kolb, J. J. *et al.* Prevalence of Positive COVID-19 Test Results Collected by Digital Self-report in the US and Germany. *JAMA Network Open* 6(1):e2253800 (2023).
 - Robert Koch Institute and Research on Complex Systems of Humboldt University of Berlin.
 Corona Data Donation https://corona-datenspende.github.io/en/.
- ⁶⁵² 24. Nalbandian, A. *et al.* Post-acute COVID-19 syndrome. en. *Nature Medicine* 27, 601–615. ISSN:
 ⁶⁵³ 1078-8956, 1546-170X. https://www.nature.com/articles/s41591-021-01283-z (2023) (Apr.
 ⁶⁵⁴ 2021).
- Michelen, M. *et al.* Characterising long COVID: a living systematic review. en. *BMJ Global Health* 6, e005427. ISSN: 2059-7908. https://gh.bmj.com/lookup/doi/10.1136/bmjgh-2021-005427
 (2023) (Sept. 2021).
- Canas, L. S. *et al.* Profiling post-COVID-19 condition across different variants of SARS-CoV2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and
 vaccinated delta-variant populations. en. *The Lancet Digital Health* 5, e421-e434. ISSN: 25897500.
 https://linkinghub.elsevier.com/retrieve/pii/S2589750023000560 (2023) (July 2023).
- Topp, C. W., Østergaard, S. D., Søndergaard, S. & Bech, P. The WHO-5 Well-Being Index: A
 Systematic Review of the Literature. en. *Psychotherapy and Psychosomatics* 84, 167–176. ISSN:
 0033-3190, 1423-0348. https://www.karger.com/Article/FullText/376585 (2023) (2015).
- WHO (World Health Organisation). WHO-5 Well-Being Index https://www.corc.uk.net/
 outcome-experience-measures/the-world-health-organisation-five-well-being-index who-5/ (2023).
- Nguyen, N. N. et al. Clinical patterns of somatic symptoms in patients suffering from post-acute long COVID: a systematic review. en. European Journal of Clinical Microbiology & Infectious Diseases 41, 515–545. ISSN: 0934-9723, 1435-4373. https://link.springer.com/10.1007/s10096-022-04417-4 (2023) (Apr. 2022).
- 30. Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P. & Diaz, J. V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. en. *The Lancet Infectious Diseases* 22, e102–e107. ISSN: 14733099. https://linkinghub.elsevier.com/retrieve/pii/S1473309921007039
 (2023) (Apr. 2022).
- 876 31. Reimers, A. K., Knapp, G. & Reimers, C.-D. Effects of Exercise on the Resting Heart Rate: A
 877 Systematic Review and Meta-Analysis of Interventional Studies. Journal of Clinical Medicine 7.
 878 ISSN: 2077-0383. https://www.mdpi.com/2077-0383/7/12/503 (2018).

All rights reserved. No reuse allowed without permission.

- 32. Huang, G., Shi, X., Davis-Brezette, J. A. & Osness, W. H. Resting heart rate changes after
 endurance training in older adults: a meta-analysis. *Medicine and science in sports and exercise*37, 1381-1386. ISSN: 0195-9131. https://journals.lww.com/acsm-msse/Fulltext/2005/
- 08000/Resting_Heart_Rate_Changes_after_Endurance.18.aspx (2005).
- Bai, F. *et al.* Female gender is associated with long COVID syndrome: a prospective cohort study. *Clinical Microbiology and Infection* 28, 611.e9-611.e16. ISSN: 1198-743X. https://www.
 sciencedirect.com/science/article/pii/S1198743X21006297 (2022).
- ⁶⁸⁶ 34. Philip, K. *et al.* Impact of COVID-19 on people with asthma: a mixed methods analysis from a ⁶⁸⁷ UK wide survey. *BMJ Open Resp Res* **9(1)**, e001056 (2022).
- Wang, S. *et al.* Associations of Depression, Anxiety, Worry, Perceived Stress, and Loneliness Prior
 to Infection With Risk of Post-COVID-19 Conditions. *JAMA Psychiatry* 79, 1081–1091 (2022).
- Atchison, C. J. *et al.* Long-term health impacts of COVID-19 among 242,712 adults in England.
 en. *Nature Communications* 14, 6588. ISSN: 2041-1723. https://www.nature.com/articles/
 s41467-023-41879-2 (2023) (Oct. 2023).
- 37. Schilling, C. et al. Pre-existing sleep problems as a predictor of post-acute sequelae of COVID-19.
 Journal of Sleep Research 33, e13949 (2024).
- Antony, B. *et al.* Predictive models of long COVID. en. *eBioMedicine* 96, 104777. ISSN: 23523964.
 https://linkinghub.elsevier.com/retrieve/pii/S2352396423003432 (2024) (Oct. 2023).
- 39. Zang, C. *et al.* Identification of risk factors of Long COVID and predictive modeling in the
 RECOVER EHR cohorts. en. *Communications Medicine* 4, 130. ISSN: 2730-664X. https://www.
 nature.com/articles/s43856-024-00549-0 (2024) (July 2024).
- 40. Yetisen, A. K., Martinez-Hurtado, J. L., Ünal, B., Khademhosseini, A. & Butt, H. Wearables
 in Medicine. en. Advanced Materials 30, 1706910. ISSN: 1521-4095. https://onlinelibrary.
 wiley.com/doi/abs/10.1002/adma.201706910 (2018).
- Adams, J. L. *et al.* A real-world study of wearable sensors in Parkinson's disease. en. *npj Parkinson's Disease* 7. Number: 1 Publisher: Nature Publishing Group, 1–8. ISSN: 2373-8057. https://www.nature.com/articles/s41531-021-00248-w (2024) (Nov. 2021).
- 42. Khondakar, K. R. & Kaushik, A. Role of Wearable Sensing Technology to Manage Long COVID.
 en. *Biosensors* 13, 62. ISSN: 2079-6374. https://www.mdpi.com/2079-6374/13/1/62 (2023)
 (Dec. 2022).
- 43. Burki, T. Wearable technology and COVID-19. en. *The Lancet Respiratory Medicine* 10, 934–935. ISSN: 22132600. https://linkinghub.elsevier.com/retrieve/pii/S2213260022003514
 (2023) (Oct. 2022).
- 44. Crook, H., Raza, S., Nowell, J., Young, M. & Edison, P. Long covid—mechanisms, risk factors, and management. en. *BMJ* 374, n1648. ISSN: 1756-1833. https://www.bmj.com/lookup/doi/
 10.1136/bmj.n1648 (2023) (July 2021).
- 45. Carvalho-Schneider, C. *et al.* Follow-up of adults with noncritical COVID-19 two months after
 symptom onset. en. *Clinical Microbiology and Infection* 27, 258-263. ISSN: 1198743X. https:
 //linkinghub.elsevier.com/retrieve/pii/S1198743X20306066 (2023) (Feb. 2021).
- 46. Wu, Q., Sum, K. & Nathan-Roberts, D. How Fitness Trackers Facilitate Health Behavior Change.
 Proceedings of the Human Factors and Ergonomics Society Annual Meeting 60, 1068–1072 (Sept. 2016).
- 47. Richard, S. *et al.* Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of
 Vaccination Before or After SARS-CoV-2 Infection. *JAMA Network Open* 6(1), e2251360 (2023).
- 48. Hernández-Aceituno, A., García-Hernández, A. & Larumbe-Zabala, E. COVID-19 long-term se quelae: Omicron versus Alpha and Delta variants. *Infectious Diseases Now* 53, 104688 (2023).

- All rights reserved. No reuse allowed without permission.
- 49. Marra, A. R. et al. The effectiveness of COVID-19 vaccine in the prevention of post-COVID con-
- ditions: a systematic literature review and meta-analysis of the latest research. en. Antimicrobial Stewardship & Healthcare Epidemiology 3, e168. ISSN: 2732-494X. https://www.cambridge.org/
 core/product/identifier/S2732494X23004473/type/journal_article (2023) (2023).
- 50. Nealon, J. & Cowling, B. J. Omicron severity: milder but not mild. en. *The Lancet* **399**, 412–413. ISSN: 01406736. https://linkinghub.elsevier.com/retrieve/pii/S0140673622000563
 (2023) (Jan. 2022).
- ⁷³² 51. Raj, S. A. *et al.* Long-COVID postural tachycardia syndrome: an American Autonomic Society
 ⁷³³ statement. *Clin Auton Res* **31**, 365–368 (2021).
- 52. Ormiston, C. K., Świątkiewicz, I. & Taub, P. R. Postural orthostatic tachycardia syndrome as a sequela of COVID-19. *Heart Rhythm* 19, 1880–1889. ISSN: 1547-5271. https://www.
- sciencedirect.com/science/article/pii/S1547527122021853 (2022).

SUPPLEMENTARY INFORMATION: WEARABLE DATA REVEALS DISTINCT CHARACTERISTICS OF INDIVIDUALS WITH PERSISTENT SYMPTOMS AFTER A SARS-COV-2 INFECTION

Supplementary Table I. Information on other diseases and conditions of all studied cohorts. See Materials and Methods (Section IV) for further details on the specifics of the assignments.

	COVID-19	COVID-19	COVID-19	COVID-19	M-COVID-19	M-COVID-19	M-COVID-19
	$[+]^1$	[-]	$[+]$ NS 2	$[+]PS^{3}$	[+]NS ⁴	[-]	[+]PS ⁵
N	7,828	12,987	$7,\!691$	137	150	150	50
% answered	89.9***	87.7	89.9***	88.3	90.0	89.3	90.0
No disease in the past 12 months $[\%]$	48.5^{***}	44.3	49.0***	24.8***	54.1	41.0	31.1^{*}
Allergies [%]	30.4	30.0	30.0	50.4^{***}	25.2	32.1	46.7^{**}
Hypertension [%]	18.2^{***}	22.6	18.1^{***}	23.1	16.3	25.4	20.0
Asthma [%]	9.3	9.3	9.0	24.0^{***}	11.1	11.9	22.2
Increased blood lipid/							
cholesterol levels [%]	10.4^{***}	12.8	10.3^{***}	15.7	8.1	12.7	17.8
Chronic Bronchitis [%]	2.1^{***}	3.1	2.0^{***}	6.6^{**}	1.5	1.5	8.9*
Other $[\%]$	10.5^{***}	13.9	10.3^{***}	19.8^{*}	10.4	9.7	22.2
Mental Illness Diagnose [%]	19.5^{**}	22.2	$19.2^{\dagger \dagger}$	39.7^{***}	15.6	20.1	44.4***

 $\frac{1}{1} COVID - 19[+] vs. COVID - 19[-]; {}^{2} COVID - 19[+]NS vs. COVID - 19[-]; {}^{3} COVID - 19[+]PS vs. COVID - 19[+]NS; {}^{4} M - COVID - 19[+]NS vs. M - COVID - 19[-]; {}^{5} M - COVID - 19[+]PS vs. M - COVID - 19[+]NS . p-values: *p ; 0.05, **p ; 0.01, ***p ; 0.001.$

perpetuity. All rights reserved. No reuse allowed without permission.



Supplementary Figure 1. Relative frequency of symptoms relative to week of reported SARS-CoV-2 test for positive cohort in blue (COVID - 19[+]) and negative control cohort (COVID - 19[-]) in black. The symptoms are fever (a), headache (b), sore throat (c), diarrhea (d), runny nose (e), cough (f), loss of smell/taste (g), limb ache (h), and chills (i). Shading indicates the 99% confidence interval, i.e. 2.576 times the standard error of a binomial distribution. Asterisks indicate significant differences between the cohorts using a two-sided two proportion z-test with a significance level of 0.01.

2



Supplementary Figure 2. Distribution of number of unique reported symptoms during acute phase of the infection (0-4 weeks to the reported SARS-CoV-2 test). We show the proportion of individuals per number of unique symptoms during the acute-phase of the infection for the persistent symptoms in pink (COVID - 19[+]PS), positive control in blue (COVID - 19[+]NS) and negative control cohort in black (COVID - 19[-]).





Supplementary Figure 3. Relative frequency per symptom. For pre- (a), acute- (b), sub-acute (c) and post (d) phase we show the relative frequency per reported symptom for all three groups in the matched cohort: negative match in black (M - COVID - 19[-]), positive match in blue (M - COVID - 19[+]NS) and persistent symptoms match in pink (M - COVID - 19[+]PS).



Supplementary Figure 4. Seasonal trends in wearable data. Exemplary timeseries of mean RHR per day (a) and mean steps per day (b) over the CDA Population for one example year (2022) and one example donation-source (Apple).

Supplementary Figure 5. High activity profiles of the *matched cohort*. Relative frequency of the number of high activity days per week relative to the SARS-CoV-2 test date for M - COVID - 19[+]PS (a),

M - COVID - 19[+]NS (b) and M - COVID - 19[-] (c). A day is defined as a high activity day when the corresponding number of steps per day exceed one standard deviation over the seasonal mean taken over the whole set of users in the Corona Data Donation Project (CDA Population).

Supplementary Figure 6. Answers to WHO-5 wellbeing and EQ-5D questionnaires before the reported SARS-CoV-2 test for the persistent symptoms (pink), positive control (blue) and negative control cohort (black). WHO-5 wellbeing (a,c-g) and modified EQ-5D/QoL (b,h-l) for the COVID - 19[+]PS (pink), COVID - 19[+]NS(blue), and COVID - 19[-] (black) cohorts before the reported SARS-CoV-2 test. The individual WHO-5 and modified EQ-5D scores were both averaged to obtain the overall wellbeing (a) and QoL (b) scores, respectively. Overall, COVID - 19[+]PS individuals reported more issues with wellbeing (c-g) and QoL (h-l) than the control cohorts. Error bars indicate standard errors.

Supplementary Figure 7. Answers to WHO-5 wellbeing and EQ-5D questionnaires after the reported SARS-CoV-2 test for the persistent symptoms (pink), positive control (blue) and negative control cohort (black). WHO-5 wellbeing (a,c-g) and modified EQ-5D/QoL (b,h-l) for the COVID - 19[+]PS (pink), COVID - 19[+]NS (blue), and COVID - 19[-] (black) cohorts after the reported SARS-CoV-2 test. The individual WHO-5 and modified EQ-5D scores were both averaged to obtain the overall wellbeing (a) and QoL (b) scores, respectively. Overall, COVID - 19[+]PS individuals reported more issues with wellbeing (c-g) and QoL (h-l) than the control cohorts. Error bars indicate standard errors.

Supplementary Figure 8. Distribution of reported SARS-CoV-2 testdates of studied cohorts. We show per month ranging from October 2021 to November 2022 the proportion of individuals who indicated their SARS-CoV-2 test in the respective month for the COVID-19[-] (negative, black), COVID-19[+] (positive, red), COVID-19[+]NS (positive control, grey), COVID-19[+]PS (persistent symptoms, pink), M-COVID-19[+]PS (persistent symptoms match, blue), M-COVID-19[+]NS (positive match, orange), and M-COVID-19[-] (negative match cohort, light black).

10

Supplementary Figure 9. Distribution of time-worn of wearable devices. Number of 15 minute heart rate measurements as a proxy for wearing time for the three age and sex matched cohorts M-COVID-19[+]PS (persistent symptoms match, blue), M-COVID-19[+]NS (positive match, pink), and M-COVID-19[-] (negative match cohort, black) in 24 hours (a) and during night time from 11pm until 6am (b).